What question did this study set out to answer?

To evaluate the outcomes on sexual function following focal brachytherapy in men with unilateral prostate cancer.

(544) Minimally Invasive, Maximally Preserved: Sexual Function After Focal Brachytherapy for Pros-Tate Cancer – Insights from the CapFIRE Trial

View Full Paper

Ask AI

Bookmark

To evaluate the outcomes on sexual function following focal brachytherapy in men with unilateral prostate cancer.
Forty men underwent targeted focal brachytherapy for prostate cancer as part of a prospective trial from January 2024 to May 2025.
Validated questionnaires assessing erectile and ejaculatory function were administered at baseline and follow-up intervals.
Data on age, changes in potency and satisfaction, and PDE-5 inhibitor use were collected.
Mean IIEF-5 score slightly declined from 20.4 to 19.6 (p=0.510); 68% retained mild/no erectile dysfunction at 6 months.
82% maintained erections sufficient for intercourse at 6 months (EHS ≥3), compared to 90% at baseline (p=0.718).
79% reported ejaculation always/often, and 82% reported orgasm always/often, indicating stable ejaculatory and orgasmic functions.

No takes yet. Share an insight, caveat, or question.

Randomized trial assesses sexual function outcomes after focal brachytherapy in men with prostate cancer, suggesting treatment benefits.

Boesen et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark